

Single- and Multiple-Dose Clinical Trials (**ASCENT-1** and **ASCENT-2**) for Dose Finding of PRX012 in Participants With Biologically Confirmed Alzheimer's Disease

ascent-1

Single-Dose Clinical Trial

Treatment: Single SC injection of PRX012 or placebo

Participants With Early AD: Amyloid PET positive, MMSE ≥ 18

Healthy Volunteers
(Aged 20-45 years)

Participants With Early AD
(Aged 60-85 years)

Randomization 3:1 (PRX012:Placebo)

Randomization 3:1 (PRX012:Placebo)

70 mg

200 mg

70 mg

200 mg

400 mg

1

Primary Objective

To evaluate the safety and tolerability of PRX012 administered as a single dose

2

Secondary Objective

To characterize the PK profile of PRX012 after SC administration as a single dose

Study Duration

~3 months

ascent-2

Multiple-Dose Clinical Trial

Treatment: Multiple SC injections of PRX012 or placebo

Participants With Early AD: Aged 55-85 years, amyloid PET eligible, MMSE ≥ 18

**Participants With Early AD -
APOE4 Non-carriers or Heterozygous**
(Group A)

**Participants With Early AD -
APOE4 Homozygous**
(Group B)*

Randomization 3:1 (PRX012:Placebo)

Randomization 3:1 (PRX012:Placebo)

45 mg

70 mg

200 mg

400 mg

45 mg

70 mg

200 mg

**Up to
400 mg**

1

Primary Objective

To evaluate the safety, tolerability, and immunogenicity of PRX012 after multiple SC doses

2

Secondary Objective

To characterize the PK profile and PD effects on brain amyloid plaque deposition of PRX012 after multiple SC doses

Study Duration

~6 months

ascent-3

Open-Label Extension Trial

Participants who complete ASCENT-1 or ASCENT-2 may be eligible to enter into the open-label extension study, **ASCENT-3**

*Group B increases representation of participants who are homozygous for APOE4 to ~2× that of the general AD population.

PRX012 is an investigational drug and not approved by any regulatory authority.

AD, Alzheimer's disease; APOE4, apolipoprotein E4; MMSE, Mini-Mental State Examination; PD, pharmacodynamic; PET, positron emission tomography; PK, pharmacokinetic; SC, subcutaneous.

Swanson C, et al. Poster presentation at AAIC 2024; July 28-August 1, 2024; Philadelphia, PA, USA. Data as of August 1, 2024.

©2024 Prothena